Interpace Biosciences, Inc. Preliminary 2025 thyroid testing revenue grew 21% over prior year Initial 2026 guidance of 16% growth in thyroid testing revenue All preferred stock converted to common stock Debt-free balance sheet and positive Net Income and EBITDA operations Company to seek uplisting on the Nasdaq Stock Market PARSIPPANY, NJ, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc.
Interpace Biosciences
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Interpace
Contact Interpace, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack